Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBE-002 in advanced solid tumors
NCT04441099Phase 2Terminated
- Sponsor
- NBE-Therapeutics
- Start
- Jun 2020
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nbe-002 in solid tumor (advanced stage) and triple-negative breast cancer (TNBC) (4 cohorts), sponsored by NBE-Therapeutics. Primary endpoints: Recommended Phase 2 Dose up to 48 months and Anti-tumor Activity up to 60 months. Started Jun 2020; status: terminated.
02
Drugs
nbe-002
03
Conditions
solid tumor (advanced stage)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04441099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04441099.